【摘要】 目的回顾性分析阿比多尔治疗普通型新型冠状病毒肺炎的疗效及安全性。方法纳入2020年1月30日至2月18日北京市朝阳区定点医院收治的所有确诊为新型冠状病毒肺炎且采用阿比多尔进行抗病毒治疗的患者,分析用药疗效、临床转归进程和不良反应发生情况。结果共纳入20例新型冠状病毒肺炎患者,入院时均为普通型确诊患者。经过治疗,9例(占45%)显效,6例(占30%)有效,5例(占25%)无效,阿比多尔抗病毒治疗的总有效率为75%。阿比多尔用药疗程平均为(6. 7±1. 6)d,退热时间平均为(4. 7±2. 0)d,呼吸道症状缓解时间平均为(5. 9±2. 5)d,首次复查核酸转阴时间平均为(6. 6±2. 7)d。20例患者中有12例(占60%)出现不良反应,9例(占45%)出现恶心、呕吐症状,8例(占40%)有腹泻症状,4例(占20%)出现血清转氨酶升高,总体症状较轻,停药或治疗后缓解。结论阿比多尔治疗普通型新型冠状病毒肺炎具有一定疗效,不良反应较轻。更多还原

【Abstract】 Objective To retrospectively assess the efficacy and safety of arbidol hydrochloride in the treatment of corona virus disease 2019(COVID-19)with common type. Methods All novel coronavirus pneumonia patients admitted in Chaoyang District designated hospital in Beijing from 2020-1-30 to 2020-2-18 were treated with antiviral treatment with hydrochloric acid. The efficacy,clinical course and adverse reactions were analyzed. Results A total of 20 novel coronavirus pneumonia patients were enrolled,all of whom were confirmed patients with normal type. After treatment,9 cases(45%)were markebly effective,6 cases(30%)were effective,5 cases(25%)were ineffective. The total effective rate of antiviral therapy with abidol hydrochloride was 75%. The average course of medication with abidol hydrochloride was(6. 7 ± 1. 6)d,the average time of fever reduction was(4. 7 ± 2. 0)d,the average time of respiratory symptom relief was(5. 9 ± 2. 5)d,and the average time of nucleic acid turning negative was(6. 6 ± 2. 7)d in the first reexamination. Among the 20 patients,12(60%)had adverse reactions,9(45%)had nausea and vomiting,8(40%)had diarrhea,4(20%)had elevated serum transaminase,the overall symptoms were mild,and the drug was stopped or relieved after treatment. Conclusions Arbidol hydrochloride can be used to treat COVID-19 with common type,and it is effective.更多还原